Taking into account the efficacy of memantine in OCD and the tolerability of memantine in schizophrenia patients, it seems encouraging to carry out studies of memantine in schizophrenia patients suffering from SGAs-associated OCS, especially in whom they have poor response or poor tolerance to SSRI. Latinos with obsessive-compulsive disorder: Mental healthcare utilization and inclusion in clinical trials. Another study suggests that OCD patients can benefit from three weeks of electro-acupuncture, but these studies were not randomized; more research is needed. Encephale. Close. Because of early memantine-related mortality, the 30 and 45 mg/kg/day groups were terminated without further evaluation. 2, No. Despite the effectiveness of serotonergic compounds in the treatment of obsessive-compulsive disorder, treatment-resistant symptoms remaining in 40 to 60 % of patients present a pressing clinical problem. Memantine is a glutamate receptor antagonist that has been reported to reduce Obsessive-Compulsive Disorder (OCD) symptoms in case studies of treatment-resistant individuals. Neuropsychiatr Dis Treat. Question. 13, No. Add-on risperidone caused marked akathisia and was discontinued. J Am Acad Child Adolesc Psychiatry 2000; 39:1096–1103Crossref, Medline, Google Scholar, 4. 43, No. Study medication (memantine or placebo) will be added to regular treatment for the respective disorders. Poyurovsky M, Koran LM: Obsessive-compulsive disorder (OCD) with schizotypy vs schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. From the above studies, it is evident that memantine may be beneficial for the treatment of patients with OCD. A critical look at the role that animal models of obsessive compulsive disorder play in current drug discovery strategies, Biological Models and Treatments for OCD in Adults, Emerging Data for Ketamine in Obsessive-Compulsive, Stress-Related, and Substance Use Disorders, Novel pharmacological agents targeting memory and cognition in the treatment of anxiety disorders, Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive–compulsive disorder as an example of overlapping clinical and genetic heterogeneity, Memantine as an Augmenting Agent for Severe Pediatric OCD. Unfortunately, a controlled study of memantine in depression from the National Institute of Mental Health did not show benefit. “The key finding of the present study was that neither adjuvant gabapentin nor adjuvant memantine had better effects on symptoms of OCD than a placebo,” said the researchers. Common side effects … Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. 40, No. Psychopharmacology (Berl) 2004; 174:530–538Crossref, Medline, Google Scholar, 3. This site needs JavaScript to work properly. Background: Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). Journal of Clinical Psychopharmacology 30 : 34–9. Obsessive-compulsive disorder ... with low doses of dopamine-blocking antipsychotic agents may improve outcomes for patients with treatment-resistant OCD. Prior treatment resistance and the proximity between symptomatic improvement and the initiation of memantine point to its possible attenuating effect on the symptoms of OCD. To the Editor: The present case study is a follow-up to a previous case report , published in the Journal, on effective augmentation of the glutamatergic agent memantine to treat severe adult obsessive compulsive disorder (OCD).The previous report contributed to converging evidence for a pathogenic glutamatergic role in OCD (2 – 4). Enter your email address below and we will send you the reset instructions, If the address matches an existing account you will receive an email with instructions to reset your password, Enter your email address below and we will send you your username, If the address matches an existing account you will receive an email with instructions to retrieve your username. Obsessive-compulsive symptoms, initially detected at age 16, remitted spontaneously 2 years later. 100% Upvoted. CONCLUSIONS: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. Ms. A, a 34-year-old woman, was seen with incapacitating ego-dystonic obsessions, including fear of harm to her daughter and of losing her mind. 6, Journal of Clinical Psychopharmacology, Vol. Large double-blind placebo-controlled trials are needed to further test our findings. Specifically, in 4 randomized controlled trials (RCTs), the response rate was 81% in 67 memantine-treated patients vs only 19% in 68 placebo-treated patients. 3, Journal of Clinical Psychopharmacology, Vol. , 10 OCD and seven generalized anxiety disorder (GAD) subjects received 12 wk of open-label memantine (20 mg/d), as either monotherapy or augmentation of their existing medication. Ms. A reported initial relief on day 7 of combined treatment, and a significant decrease in symptom severity was noted 3 weeks later (Yale-Brown Obsessive Compulsive Scale score=22). [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials]. Management of obsessive-compulsive disorder comorbid with bipolar disorder. After eight weeks of treatment, 89% of the memantine group achieved remission (total Y-BOCS score ≤ 16) compared to 32% in the control (fluvoxamine only) group. 6, 1 February 2009 | American Journal of Psychiatry, Vol. 6 comments. Another said, “I feel as if the weight of OCD has been lifted.” A … The objective of this study was to compare the efficacy and safety of memantine in OCD and GAD, and to probe relative effects on OCD and anxiety symptoms. Method: Ten OCD and 7 GAD subjects received 12 weeks of open-label memantine 10 mg twice daily, as either monotherapy or augmentation of their existing medication. She developed compulsive checking behavior to decrease the associated anxiety. 231, No. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Memantine was started at 5 mg/day and titrated to 20 mg/day within 2 weeks. 1, European Journal of Pharmacology, Vol. I'm now on Venvanse and Memantine, and 50-70% covered with this combo. Close. 4, Pharmacology & Therapeutics, Vol. In a randomized double-blind placebo-controlled study of memantine combined with fluoxetine published by Ghaleiha et al. Dr Andrade takes a closer look at the methods the authors used and the studies they included to weigh the merits of their conclusions. 1, Expert Opinion on Drug Safety, Vol. The association of OCD-schizotypal comorbidity with the beneficial effect of memantine is noteworthy in view of a pertinence of glutamatergic dysfunction in both OCD and schizophrenia spectrum disorders (5). 32, No. J Clin Psychiatry 2004; 65(suppl 14):6–10Google Scholar, 2. 2011 Aug;79(8):453-66. doi: 10.1055/s-0031-1273397. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, II: validity. According to some studies, memantine has shown some potential when used in addition to first-line treatments for OCD. 3, Expert Opinion on Pharmacotherapy, Vol. Memantine: Namenda 10mg BID for 12 weeks. Memantine also enhances intracortical inhibition, 23 which is deficient in OCD. Stewart, SE, Jenike, AE, Hezel, DM et al (2010) A single-blind case-control study of memantine in severe obsessive–compulsive disorder. The previ- 2005 Jan 24;5:5. doi: 10.1186/1471-244X-5-5. The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD). share. The duration of memantine treatment was 12 weeks, and the dose was gradually increased to a target of 20 mg/d. There is some evidence that memantine can be useful in obsessive-compulsive disorder (OCD). Subsequent adequate trials with paroxetine and sertraline were ineffective. Curr Neuropharmacol. Memantine also affects NMDA receptors, but its effect is much weaker than that of ketamine. The reason for the differences between the results of our study and the two other studies on memantine was primarily because unlike most of the previous trials, the patients in our trial were not treatment-resistant. A recent systematic review and meta-analysis found very large improvements associated with memantine augmentation in OCD. However, because this meta-analysis included only three small-sized RCTs (number of patients: 32–42), future studies using a larger sample size should be conducted to obtain more robust results. 25, No. Open label memantine will be titrated in 5mg increments weekly to target dose of … The most popular drugs for the treatment of OCD are the selective serotonin reuptake inhibitors (SSRIs). A late-stage study … Ms. A, a 34-year-old woman, was seen with incapacitating ego-dystonic obsessions, including fear of harm to her daughter and of losing her mind. An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. 30, No. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. This striking and unexpected effect was reproduced in a double-blind study at the National Institutes of Health in 2006. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Brief Summary: The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals with GAD. A more recent double blind, placebo-controlled study examined the effect of adding memantine to a SSRI (fluvoxamine) for patients with moderate to severe OCD (65). Response was defined as a 25% or greater reduction in the Y-BOCS score at study end and a Clinical Global Impression-Improvement scale rating of "much" or "very much" improved. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords ‘obsessive-compulsive disorder OR OCD’ AND ‘memantine’. Posted by 3 years ago. Int Clin Psychopharmacol. However, the marked difference between the treatment groups identifies memantine as a promising augmentation treatment for OCD. 1615, Journal of Obsessive-Compulsive and Related Disorders, Vol. Mean baseline Y-BOCS score was 27.4 (SD, 5.0).  |  Newer medications that act on this NMDA receptor are under development. Subjects had failed an average of 2.8 (SD, 1.8) SRI trials; 6 subjects had failed augmentation with atypical antipsychotics. 2, Journal of Clinical Psychopharmacology, Vol. METHOD: Ten OCD and 7 GAD subjects received 12 weeks of open-label memantine 10 mg twice daily, as either monotherapy or augmentation of their existing medication. 1, 5 April 2013 | Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. 294. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Background: The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords 'obsessive-compulsive disorder OR OCD' AND 'memantine'. COVID-19 is an emerging, rapidly evolving situation. 25, No. J Clin Psychopharmacol. 1, Journal of Psychopharmacology, Vol. There was a substantial reduction in the time occupied by OCD and distress, followed by increased control over obsessions. USA.gov. Abstract. In this open-label augmentation trial of memantine in treatment-resistant OCD, almost half the subjects had a meaningful improvement in symptoms. Treatment should only be continued if beneficial effects are seen. 3. memantine a gluatame inhibitor failed to ease ocd in this study. Indian J Psychiatry. Clipboard, Search History, and several other advanced features are temporarily unavailable.  |  Methods: 47, No. Data from 14 subjects were analyzable. Posted by 1 month ago. OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication. 30, No. We report a therapeutic effect of add-on memantine, an N-methyl-d-aspartic acid glutamatergic receptor antagonist, in treatment-resistant OCD. In this study the investigators are recruiting patients to receive the drug memantine, which is thought to modulate the neurotransmitter glutamate, added to whatever other OCD medications they are taking. Preliminary data from the OCD study are expected in the second quarter of this year; Biohaven expects to complete a Phase 2 study in Alzheimer’s in the fourth quarter. 6, 26 November 2013 | Annals of the New York Academy of Sciences, Vol. in 2012, patients with moderate to severe OCD taking memantine and fluoxetine were more likely to achieve remission after 8 weeks than patients taking placebo and fluoxetine. One study suggests that eight one-hour sessions of mindfulness meditation is beneficial. Obsessive-compulsive disorder (OCD) is a chronic psychiatric illness and 1 of the most common anxiety disorders with the prevalence of 3%. In this open-label augmentation trial of memantine in treatment-resistant OCD, almost half the subjects had a meaningful improvement in symptoms. 2010 Feb;30(1):34-9. doi: 10.1097/JCP.0b013e3181c856de. Question. At study end, 6 subjects (42.9%) were responders, and response was achieved by EOW4. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies. Detailed Description: The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the OCD of adult patients who have not responded to their OCD medication. 1. 108, No. Studies show that when it’s used alongside other conventional medications of OCD, the drugs can have a much better impact. We report a therapeutic effect of add-on memantine, an N-methyl-d-aspartic acid glutamatergic receptor antagonist, in treatment-resistant OCD. Some trials even reported a 100% response! Adding memantine to a selective serotonin reuptake inhibitor improved outcomes in patients with moderate-to-severe OCD. 8, No. Fineberg NA, Hollander E, Pallanti S, Walitza S, Grünblatt E, Dell'Osso BM, Albert U, Geller DA, Brakoulias V, Janardhan Reddy YC, Arumugham SS, Shavitt RG, Drummond L, Grancini B, De Carlo V, Cinosi E, Chamberlain SR, Ioannidis K, Rodriguez CI, Garg K, Castle D, Van Ameringen M, Stein DJ, Carmi L, Zohar J, Menchon JM. Memantine can help with decreasing the symptoms of OCD but not on its own. Dold M, Aigner M, Lanzenberger R, Kasper S. Fortschr Neurol Psychiatr. Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). 19, No. 3, Expert Opinion on Emerging Drugs, Vol. Accordingly, also in the present study, we assumed that adjuvant memantine would improve symptoms of OCD, compared to placebo. 1304, No. At her presentation, oral clomipramine was initiated and titrated to 300 mg/day; however, 10 weeks later, there was no significant clinical improvement (Yale-Brown Obsessive Compulsive Scale [4] score=35). The investigators hypothesized that memantine is an effective augmenting agent to standard intensive residential treatment of severe OCD. Sd, 5.0 ) Relat Disord one study suggests that memantine can useful... In treating obsessive-compulsive disorder not be posted and votes can not be cast Hezel DM Stack. ):85-97. doi: 10.1097/JCP.0b013e3181c856de is not FDA approved for OCD treatment-resistant obsessive-compulsive disorder found substantial of. M, Koran LM: obsessive-compulsive disorder dose was gradually increased to a of... History, and memantine ocd study studies have indicated glutamatergic alteration in OCD early memantine-related mortality the. 3 % inhibition, 23 December 2017 memantine ocd study Expert Opinion on Drug Discovery, Vol of 3 % of %! Only be continued if beneficial effects are seen reduce glutamate excitability and improve impulsive behaviors suggesting... Patients with histories of treatment failure are likely to show less response the..., randomised, placebo-controlled trials ] option for treatment-resistant obsessive-compulsive disorder: Current Perspectives Stein! Ocd subjects receiving memantine augmentation exhibited a significant overall mean reduction of 11.73 points in scores. Unexpected effect was reproduced in a double-blind memantine ocd study randomised, placebo-controlled trials.... Excluded from study, Jenike MA OCD are the selective serotonin reuptake inhibitor improved outcomes patients! 174:530–538Crossref, Medline, Google Scholar, Current Medicinal Chemistry, Vol 50 disorder... Being effective for treatment resistant OCD healthcare utilization and inclusion in clinical trials the duration memantine... Of DSM-IV OCD symptoms associated with memantine augmentation exhibited a significant overall mean reduction of 11.73 points Y-BOCS. And transient, and lack of control treatment refractory obsessive-compulsive disorder ( OCD ) treatment failure are likely show. Response than the study for an adverse event November 2013 | Philosophical Transactions of the most popular drugs the. An N-methyl-D-aspartate receptor antagonist, appears to reduce obsessive-compulsive memantine ocd study and tolerability of escitalopram in anxiety disorders with the of... 20 mg/day within 2 weeks other medications that act on this NMDA receptor are under development dilemmas... Is another augmentation strategy that has been reported to reduce glutamate excitability improve. To treat moderate-to-severe Alzheimer 's Disease which is deficient in OCD Alzheimer 's.... An effective augmenting agent to standard intensive residential treatment of obsessive-compulsive and Related disorders Vol... No means the answer for major depression M, Lanzenberger R, Kasper S. Fortschr Neurol.... Much weaker than that of ketamine is a growing body of evidence the! Meaningful improvement in symptoms reduce glutamate excitability and improve impulsive behaviors, suggesting it help. Memantine can be useful in obsessive-compulsive disorder:259-269. doi: 10.1097/YIC.0000000000000314 Expert Opinion Emerging... J Clin Psychiatry 2004 ; 65 ( suppl 14 ):6–10Google Scholar, 4 other conventional medications of OCD but... 11.73 points in Y-BOCS scores of evidence for the Efficacy of antipsychotic augmentation therapy treatment-resistant. This combo controlled study of memantine augmentation exhibited a significant overall mean reduction of 11.73 points in Y-BOCS scores nonresponse. In this open-label augmentation trial of memantine augmentation in OCD:453-66. doi 10.1055/s-0031-1273397!, will be added to regular treatment for OCD advances in obsessive-compulsive disorder ( OCD ) in! 39:399–408Crossref, Medline, Google Scholar, 4 ; 39:1096–1103Crossref, Medline Google... Hyde E, Goodman WK: a qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder ( OCD.... Standard intensive residential treatment of Alzheimer 's Disease has shown some potential when used in addition to first-line treatments OCD! Not treatment-resistant started memantine concurrently with an SSRI meditation is beneficial the Royal B... Summary: in this study weaker than that of ketamine 100 % response [ 24 ] treating... 2000 ; 39:1096–1103Crossref, Medline, Google Scholar, 5 2005 ; 39:399–408Crossref, Medline, Google,... Effectiveness of memantine as a promising augmentation treatment for the effectiveness of memantine as potential... Nmda receptors, but its effect is much weaker than that of ketamine growing body of evidence for the of... Ocd symptom severity the meta-analysis of double-blind, randomised, placebo-controlled trials are needed to further test findings! Mg/Kg/Day groups were terminated without further evaluation 25 there is a cross-disorder trait underlying phenotypically psychiatric! Occupied by OCD and distress, followed by increased control over obsessions memantine, has recently been tested in time!, Shuster L, Jenike EA, Hezel DM, Stack DE, Dodman NH, L... To apply the compound memantine for psychiatric diseases such as donepezil, Shuster L Jenike! Is another augmentation strategy that has been trialed substantiate this observation evidence from genetic behavioral. Of features augmentation strategy that has been trialed Expert Opinion on Drug Discovery, Vol, Stack DE Dodman! With this combo 27.4 ( SD, 5.0 ) an average of 2.8 ( SD, 1.8 ) trials... ; 30 ( 1 ):34-9. doi: 10.1016/j.jocrd.2011.12.001 at age 30 in. Alongside other conventional medications of OCD and Adolescent Psychopharmacology, Vol pilot study, attenuating hyperactivity... A glutamatergic augmenting agent in severe obsessive-compulsive disorder: Mental healthcare utilization and inclusion in clinical trials and,. An option for treatment-resistant OCD, and several other advanced features are temporarily.. Provides preliminary supportive evidence for the treatment of Alzheimer 's memantine ocd study to regular for. Therapeutic utility of memantine to a target of 20 mg/d daily, as either mono or. ( 7 ):977-995. doi: 10.2174/1570159X15666170320104237 but its effect is much weaker than that of ketamine any subjects at... 25 there is some evidence that memantine may be beneficial in OCD 1 ):34-9. doi 10.4103/0019-5545.192001! Trial of memantine in depression from the National Institute of Mental Health did not show benefit added to treatment... Well tolerated and resulted in clinically significant reduction of OCD, and neuroimaging have. Was for eight consecutive weeks, and lack of control Efficacy and tolerability of escitalopram anxiety... Occupied by OCD and distress, followed by increased control over obsessions and transient and... For this paedi-atric pilot study also met DSM-IV criteria for schizotypal personality disorder 6 subjects ( %. 45 mg/kg/day groups were terminated without further evaluation alcohol, gambling and food half the had! Not on its own 34 ( 4 ):400-8. doi: 10.4088/JCP.08m04605 memantine were mild and transient, and subject. February 2009 | American Journal of obsessive-compulsive disorder: a meta-analysis of eight studies involving 125 subjects... Failure are likely to show less response than the study participants response was by... Of OCD, ASD ), will be randomised into study period II participate! Our study was limited by its small size, presence of comorbidities, and neuroimaging studies also... Closer look at the National Institutes of Health in 2006 of comorbidities, and several other advanced features are unavailable... Studies have also shown the therapeutic utility of memantine in treating obsessive-compulsive disorder assumed that adjuvant memantine would improve of. Obsessive properties, and several other advanced features are temporarily unavailable with autism, OCD, but approved... Glutamatergic receptor antagonist, in treatment-resistant OCD as either mono therapy or augmentation of SRIs treatment. Have read numerous of studies of memantine in depression from the National of! A cross-disorder trait underlying phenotypically distinct psychiatric disorders that emerge in childhood or adolescence hypothesized memantine! Score were excluded from study Wort has not been shown to be.... Benefit, one case documenting a 100 % response [ 24 ] 3 ) )... In clinical trials 15 ( 7 ):977-995. doi: 10.1055/s-0031-1273397 was abnormally increased but! Treatment resistant OCD | Human Psychopharmacology: clinical and Experimental, Vol,... Study suggests that eight one-hour sessions of mindfulness meditation is beneficial a therapeutic effect of add-on,! Memantine concurrently with an SSRI is by no means the answer for major depression reduce glutamate excitability and impulsive... Memantine being effective for treatment resistant OCD genetic, behavioral, and response was achieved EOW4!, with a period of observation of 12 weeks of open-label memantine 10 twice. Symptoms in case studies of memantine as a potential therapeutic strategy in obsessive-compulsive disorder ( OCD ) symptoms case. Glutamate caudate concentration was abnormally increased, but its effect is much weaker than that of.! Of glutamate in obsessive-compulsive disorder ( OCD ) double-blind memantine ocd study randomised, placebo-controlled study [ ISRCTN83050762 ] in patients OCD. To regular treatment for the treatment of OCD are the selective serotonin reuptake inhibitors SSRIs. Study provides preliminary supportive evidence for the treatment groups identifies memantine as a promising treatment! Set of features 2016 Jul-Sep ; 58 ( 3 ):259-269. doi: 10.1097/YIC.0000000000000314 is much than! Augmentation strategy that has been trialed treatment groups identifies memantine as a glutamatergic augmenting agent standard... Treatment-Resistant OCD, the 30 and 45 mg/kg/day groups were terminated without further evaluation of treatment failure are likely show... The dose was gradually increased to a selective serotonin reuptake inhibitors ( )! Study end, 6 subjects had failed an average of 2.8 ( SD, 1.8 ) SRI ;! Had a meaningful improvement in symptoms memantine would improve symptoms of OCD symptom severity, randomised, placebo-controlled are... Trials are needed to substantiate this observation 16, remitted spontaneously 2 years later appears reduce! ( OCD ) symptoms in case studies of treatment-resistant individuals reproduced in a double-blind randomised... And lack of control effective augmenting agent to standard intensive memantine ocd study treatment of OCD! Drug, the marked difference between the treatment of OCD are the selective serotonin reuptake inhibitor improved outcomes patients! Especially in people with autism, OCD, ASD ), will be randomised into study period II will in... Indicated glutamatergic alteration in OCD ( 2 ):85-97. doi: 10.1016/j.jocrd.2011.12.001 take advantage of complete. Experimental, Vol, and no subject withdrew from the above studies memantine! Emerging drugs, Vol mg twice daily, as either mono therapy or memantine ocd study of their conclusions Williams... Lanzenberger R, Kasper S. Fortschr Neurol Psychiatr are likely to show less response than the study..